$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens, but presumably does not produce co-stimulatory factors; PV-10 produces antigens + multiple co-stimulatory factors, such as DAMPs (damage-associated molecular patterns)
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigenic material without the context of the TME (tumor microenvironment); PV-10 produces antigens from within the TME
1/ Continuing our thread about what we believe are the differences between $PVCT’s intratumoral (ITU) PV-10 cancer immunotherapy and $MRNA intramuscular (IM) mRNA-4157 cancer vaccine. #rosebengal #rosebengalsodium.
2/ The Venn diagrams below illustrate the immune activation potential as a proportion of the total available drivers of anti-tumor activation of [LEFT] $MRNA’s IM mRNA-4157 [yellow] and [RIGHT] $PVCT’s ITU PV-10 [magenta]. Delivering Small Molecule I...Delivering Small Molecule I...
3/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #1: the extent of tumor epitopes sampled when creating mRNA-4157 from and for a patient vs the extent sampled when injecting multiple tumors of each and every patient with PV-10.
4/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #2: the single mode of activation (i.e., only antigen production) by mRNA-4157 vs an orchestrated, multimodal activation (i.e., release of tumor antigens & immune upregulating agents) by PV-10.
5/a $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #3: $MRNA’s mRNA-4157 activation is divorced from the context of actual tumor tissue. mRNA-4157 is administered intramuscularly, which is not necessarily proximate to tumor tissue.
5/b Whereas, the signaling resulting from $PVCT’s ITU PV-10 is released from actual tumor because the actual tumor is injected with PV-10. #rosebengal #rosebengalsodium.
5/c Impacting actual tumor tissue (by $PVCT’s ITU PV-10’s injection) is likely to have secondary influence on the recruitment of immune components (such as dendritic cells) and effective training of an adaptive response (i.e., functional CD8+ T cells) against tumor.
6a/ The illustrations below endeavor to characterize what appears to be the one-size-fits-all nature of $MRNA’s IM mRNA-4157 [LEFT], which is precisely matched to a subset of potential immune markers from a specific tumor, compared to $PVCT’s ITU PV-10 [RIGHT]. Delivering Small Molecule I...Delivering Small Molecule I...
6b/ $MRNA’s IM mRNA-4157’s precision may actually compromise activity against other tumor epitopes (i.e., genomic variants, which are represented by different size nuts in the LEFT illustration).
6c/ In contrast, by deploying $PVCT’s ITU PV-10 against a broad range of a patient's tumor burden (the RIGHT illustration), precise education of the immune system to produce T cells functional against each injected tumor epitope is possible.
7/ $PVCT’s ITU PV-10 seems more personalized, more precise… #rosebengal #rosebengalsodium. #PrecisionMedicine.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc. Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ProvectusBio

Mar 26, 2023
1/ 2023 Association for Research in Vision and Ophthalmology Annual Meeting. arvo.org/annual-meeting/. Accepted abstracts from Ophthalmic Biophysics Center about its Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). #ARVO23 #ARVO2023. @BascomPalmerEye @UMiamiHealth. A… twitter.com/i/web/status/1…
2/ Abstract Number: 606 - B0243. Echeverri Tribin F et al. Inhibition of Multidrug-Resistant Pseudomonas aeruginosa with Rose Bengal Photodynamic Antimicrobial Therapy: In vitro. Conclusions: MDR Pseudomonas aeruginosa can be inhibited by rose bengal eppro02.ativ.me/web/page.php?p…twitter.com/i/web/status/1…
3/ Abstract Number: 609 - B0246. Krishna et al. In vitro Inhibition of Aspergillus and Fusarium Species with Erythrosin B, Eosin Y, and Rose Bengal Photodynamic Antimicrobial Therapy. Conclusions: EB, EY, and RB with light were effective against both F. eppro02.ativ.me/web/page.php?p…twitter.com/i/web/status/1…
Read 7 tweets
Mar 25, 2023
1/ $PVCT’s Modernized #SmallMolecule #RoseBengal: A #DrugSubstance, and #ActivePharmaceuticalIngredient for 21st Century #DrugDevelopment. A THREAD.
2/ “Everyone” seems to know or understand #RoseBengal, but do they (you) really?
3/ #RoseBengal is a small molecule (i.e., <1,000 Daltons*), but a “heavy” one at 973.67 Da or g/mol. It is heavy because of its four iodides, which comprise 52% of its molecular weight.
Read 45 tweets
Mar 22, 2023
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
3/ The CTLA-4 asset BioNTech acquired is ONC-392. See here from #SITC21: jitc.bmj.com/content/jitc/9….
Read 17 tweets
Mar 8, 2023
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews @USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1… DePalo DK, Zager JS. Advances in Intralesional Therapy for L
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma © 2023, Provectus Biopharmaceuticals, Inc. https://www.prov
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-refractory advanced melanoma © 2023, Provectus Biopharmaceuticals, Inc. https://www.prov
Read 5 tweets
Mar 6, 2023
1/ $PVCT’s PV-10 (#RoseBengalSodium) Immuno-Oncology Cycle & PD-1-Combination Mechanism. A #THREAD. #InduceAndBoost.
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda #Opdivo #otherPD1s #PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
Read 18 tweets
Feb 17, 2023
1/ The impact of #Covid on $PVCT’s R&D, #DrugDiscovery, and clinical development of our #HalogenatedXanthene (#HX) medical science platform and #RoseBengalSodium (#RBS) investigational drug & drug formulation pipeline. A #THREAD.
2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
3/ #Covid has been a deeply painful experience, to say the least, for the U.S. and the world. It also marked a turning point in the advancement and expansion of our #HX medical science platform, as well as our lead molecule #RoseBengalSodium and the investigational drugs and drug… twitter.com/i/web/status/1…
Read 63 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(